Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
Inger S. Nijhof(St. Antonius Ziekenhuis), Niels W.C.J. van de Donk(Oncode Institute)
Cited by 266
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
CD38 antibodies in multiple myeloma: back to the future
|Blood|2017|482
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
|Blood|2016|377
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266